echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > No warsaw Kubaqu/Pyosatan is supported by the FDA Advisory Board to treat blood-shooting scores to preserve heart failure

    No warsaw Kubaqu/Pyosatan is supported by the FDA Advisory Board to treat blood-shooting scores to preserve heart failure

    • Last Update: 2021-01-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The Committee's positive decision was based on Entersto's overall analysis of efficacy and safety.
    includes phase III studies (PARAGON-HF) active control subgroup analysis results for HFpEF patients and Phase II studies (PARAMOUNT) results, as well as evidence of the efficacy of Phase III PARA (PARADIGM-HF) studies for HFrEF patients.
    PARAGON-HF results show that Entresto has important clinical benefits for HFpEF patients and is safe, consistent with HFrEF's extensive clinical studies and post-market experience.
    July 2017, Entresto was approved by NMPA to be listed in China for the treatment of patients with decreased shot blood fraction heart failure (HFrEF).
    heart failure (HF) is a serious ongoing disease that affects about 26 million people worldwide, mainly in the HFpEF and HFrEF categories, both of which have the same number of patients.
    , HFpEF is a special type of HF that causes the heart muscle to contract normally, but the chamber does not relax as it does when the chamber is full/relaxed.
    HFpEF may be associated with high hospitalization, low quality of life and high mortality, and is becoming the main form of HF.
    currently has no approved HFpEF therapy.
    David Soergel, M.D., Global Head of Cardiovascular, Kidney and Metabolic Drug Development at Novart, said, "We are committed to fulfilling our commitment through a wide range of clinical research projects on heart failure.
    encouraged by the latest feedback from the Committee.
    we thank patients and patient organizations for their valuable advice on this serious disease and look forward to the FDA's decision on this new adaptation.
    " According to the Pharmaceutical Rubik's Cube NextPharma database, Entresto's global sales in 2019 amounted to $1,726 million.
    content Source: Medical Rubik's Cube Info
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.